Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states

Epiregulon:利用单细胞转录因子活性推断预测药物反应和细胞状态驱动因素

阅读:3
作者:Tomasz Włodarczyk,Aaron Lun,Diana Wu,Minyi Shi,Xiaofen Ye,Shreya Menon ,Shushan Toneyan,Kerstin Seidel,Liang Wang,Jenille Tan,Shang-Yang Chen,Timothy Keyes,Aleksander Chlebowski,Adrian Waddell,Wei Zhou,Yangmeng Wang,Qiuyue Yuan,Yu Guo,Liang-Fu Chen,Bence Daniel,Antonina Hafner,Meng He,Alejandro Chibly,Yuxin Liang,Zhana Duren,Ciara Metcalfe,Marc Hafner,Christian W Siebel,M Ryan Corces ,Robert Yauch,Shiqi Xie,Xiaosai Yao

Abstract

Transcription factors (TFs) and transcriptional coregulators are emerging therapeutic targets. Gene regulatory networks (GRNs) can evaluate pharmacological agents and identify drivers of disease, but methods that rely solely on gene expression often neglect post-transcriptional modulation of TFs. We present Epiregulon, a method that constructs GRNs from single-cell ATAC-seq and RNA-seq data for accurate prediction of TF activity. This is achieved by considering the co-occurrence of TF expression and chromatin accessibility at TF binding sites in each cell. ChIP-seq data allows motif-agonistic activity inference of transcriptional coregulators or TF harboring neomorphic mutations. Epiregulon accurately predicted the effects of AR inhibition across different drug modalities including an AR antagonist and an AR degrader, delineated the mechanisms of a SMARCA4 degrader by identifying context-dependent interaction partners, and prioritized drivers of lineage reprogramming and tumorigenesis. By mapping gene regulation across various cellular contexts, Epiregulon can accelerate the discovery of therapeutics targeting transcriptional regulators.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。